Psoriasis

>

Latest News

Investigational Oral IL-23 Receptor Antagonist Improves Skin Clearance in Psoriasis: Daily Dose / image credit: ©New Africa/AdobeStock
Investigational Oral IL-23 Receptor Antagonist Improves Skin Clearance in Psoriasis: Daily Dose

August 25th 2025

Your daily dose of the clinical news you may have missed.

Investigational Oral IL-23 Receptor Antagonist Icotrokinra Improves Skin Clearance in Psoriasis in Phase 3 Study / image credit Robert Bissonnette, MD, International Eczema Council
Investigational Oral IL-23 Receptor Antagonist Icotrokinra Improves Skin Clearance in Psoriasis in Phase 3 Study

August 11th 2025

Roflumilast Foam 0.3% Update: Pivotal Phase 3 Trial Outcomes Published in JAMA Dermatology, Arcutis Announces / image courtesy of Arcutis
Roflumilast Foam 0.3% Update: Pivotal Phase 3 Trial Outcomes Published in JAMA Dermatology, Arcutis Announces

May 8th 2025

April Issue of Patient Care Digital Edition is Now Live
April Issue of Patient Care Digital Edition is Now Live

March 27th 2025

Tildrakizumab Shows Efficacy for Nail Psoriasis in Phase 3b Trial
Tildrakizumab Shows Efficacy for Nail Psoriasis in Phase 3b Trial

March 7th 2025

More News

New Study Suggests Patient Benefit Index Complements Traditional Psoriasis Outcome Measures / image credit ©InfiniteStudio/AdobeStock

New Study Suggests Patient Benefit Index Complements Traditional Psoriasis Outcome Measures

Sydney Jennings
January 20th 2025

Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.

© 2025 MJH Life Sciences

All rights reserved.